301 related articles for article (PubMed ID: 36441901)
1. Tumor Microenvironment-Activable Manganese-Boosted Catalytic Immunotherapy Combined with PD-1 Checkpoint Blockade.
Zhao Z; Dong S; Liu Y; Wang J; Ba L; Zhang C; Cao X; Wu C; Yang P
ACS Nano; 2022 Dec; 16(12):20400-20418. PubMed ID: 36441901
[TBL] [Abstract][Full Text] [Related]
2. Outer membrane vesicle-wrapped manganese nanoreactor for augmenting cancer metalloimmunotherapy through hypoxia attenuation and immune stimulation.
Luo S; Yang Y; Chen L; Kannan PR; Yang W; Zhang Y; Zhao R; Liu X; Li Y; Kong X
Acta Biomater; 2024 Jun; 181():402-414. PubMed ID: 38734282
[TBL] [Abstract][Full Text] [Related]
3. Hydrazide-manganese coordinated multifunctional nanoplatform for potentiating immunotherapy in hepatocellular carcinoma.
Hou G; Qian J; Guo M; Xu W; Wang J; Wang Y; Suo A
J Colloid Interface Sci; 2022 Dec; 628(Pt B):968-983. PubMed ID: 36037718
[TBL] [Abstract][Full Text] [Related]
4. Augmenting Immunotherapy via Bioinspired MOF-Based ROS Homeostasis Disruptor with Nanozyme-Cascade Reaction.
Wang R; Qiu M; Zhang L; Sui M; Xiao L; Yu Q; Ye C; Chen S; Zhou X
Adv Mater; 2023 Dec; 35(49):e2306748. PubMed ID: 37689996
[TBL] [Abstract][Full Text] [Related]
5. Phenolic immunogenic cell death nanoinducer for sensitizing tumor to PD-1 checkpoint blockade immunotherapy.
Xie L; Wang G; Sang W; Li J; Zhang Z; Li W; Yan J; Zhao Q; Dai Y
Biomaterials; 2021 Feb; 269():120638. PubMed ID: 33421711
[TBL] [Abstract][Full Text] [Related]
6. Genetically Edited Cascade Nanozymes for Cancer Immunotherapy.
Zhang J; Pan Y; Liu L; Xu Y; Zhao C; Liu W; Rao L
ACS Nano; 2024 May; 18(19):12295-12310. PubMed ID: 38695532
[TBL] [Abstract][Full Text] [Related]
7. Janus Silica Nanoparticle-Based Tumor Microenvironment Modulator for Restoring Tumor Sensitivity to Programmed Cell Death Ligand 1 Immune Checkpoint Blockade Therapy.
Lin X; Li F; Guan J; Wang X; Yao C; Zeng Y; Liu X
ACS Nano; 2023 Aug; 17(15):14494-14507. PubMed ID: 37485850
[TBL] [Abstract][Full Text] [Related]
8. Two-pronged microenvironmental modulation of metal-oxidase cascade catalysis and metabolic intervention for synergistic tumor immunotherapy.
Song Q; Gao H; Sun S; Li Y; Wu X; Yang J; Wang B; Zhang Y; Wang L
Acta Biomater; 2024 Jan; 173():378-388. PubMed ID: 37925121
[TBL] [Abstract][Full Text] [Related]
9. T cell-mediated targeted delivery of tadalafil regulates immunosuppression and polyamine metabolism to overcome immune checkpoint blockade resistance in hepatocellular carcinoma.
Wang X; Zhang Q; Zhou J; Xiao Z; Liu J; Deng S; Hong X; Huang W; Cai M; Guo Y; Huang J; Wang Y; Lin L; Zhu K
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36813307
[TBL] [Abstract][Full Text] [Related]
10. Immunomodulation-Enhanced Nanozyme-Based Tumor Catalytic Therapy.
Xu B; Cui Y; Wang W; Li S; Lyu C; Wang S; Bao W; Wang H; Qin M; Liu Z; Wei W; Liu H
Adv Mater; 2020 Aug; 32(33):e2003563. PubMed ID: 32627937
[TBL] [Abstract][Full Text] [Related]
11. Nanodroplet-enhanced sonodynamic therapy potentiates immune checkpoint blockade for systemic suppression of triple-negative breast cancer.
Wu W; Xu M; Qiao B; Huang T; Guo H; Zhang N; Zhou L; Li M; Tan Y; Zhang M; Xie X; Shuai X; Zhang C
Acta Biomater; 2023 Mar; 158():547-559. PubMed ID: 36539109
[TBL] [Abstract][Full Text] [Related]
12. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
[TBL] [Abstract][Full Text] [Related]
13. Enhancing photodynamic immunotherapy by reprograming the immunosuppressive tumor microenvironment with hypoxia relief.
He M; Zhang M; Xu T; Xue S; Li D; Zhao Y; Zhi F; Ding D
J Control Release; 2024 Apr; 368():233-250. PubMed ID: 38395154
[TBL] [Abstract][Full Text] [Related]
14. Multifunctional Calcium-Manganese Nanomodulator Provides Antitumor Treatment and Improved Immunotherapy via Reprogramming of the Tumor Microenvironment.
Luo G; Li X; Lin J; Ge G; Fang J; Song W; Xiao GG; Zhang B; Peng X; Duo Y; Tang BZ
ACS Nano; 2023 Aug; 17(16):15449-15465. PubMed ID: 37530575
[TBL] [Abstract][Full Text] [Related]
15. Transformable prodrug nanoplatform
Yang W; Yi J; Zhu R; Guo Y; Zhang K; Cao Y; Li X; Zhang J; Zhang Z; Li Y; Chen X
Theranostics; 2023; 13(6):1906-1920. PubMed ID: 37064869
[No Abstract] [Full Text] [Related]
16. Nonferrous Ferroptosis Inducer Manganese Molybdate Nanoparticles to Enhance Tumor Immunotherapy.
Lei H; Li Q; Pei Z; Liu L; Yang N; Cheng L
Small; 2023 Nov; 19(45):e2303438. PubMed ID: 37420331
[TBL] [Abstract][Full Text] [Related]
17. CU06-1004-Induced Vascular Normalization Improves Immunotherapy by Modulating Tumor Microenvironment
Park S; Oh JH; Park DJ; Zhang H; Noh M; Kim Y; Kim YS; Kim H; Kim YM; Ha SJ; Kwon YG
Front Immunol; 2020; 11():620166. PubMed ID: 33584714
[TBL] [Abstract][Full Text] [Related]
18. Tumor Microenvironment-Activated Nanocomposite for Self-Amplifying Chemodynamic/Starvation Therapy Enhanced IDO-Blockade Tumor Immunotherapy.
Bian Y; Liu B; Ding B; Wang M; Yuan M; Ma P; Lin J
Adv Sci (Weinh); 2023 Dec; 10(34):e2303580. PubMed ID: 37807763
[TBL] [Abstract][Full Text] [Related]
19. Catalytically Active Metal-Organic Frameworks Elicit Robust Immune Response to Combination Chemodynamic and Checkpoint Blockade Immunotherapy.
Wang X; Luo J; Wang J; Cao J; Hong Y; Wen Q; Zeng Y; Shi Z; Ma G; Zhang T; Huang P
ACS Appl Mater Interfaces; 2023 Feb; 15(5):6442-6455. PubMed ID: 36700645
[TBL] [Abstract][Full Text] [Related]
20. An ultrasound-activated nanoplatform remodels tumor microenvironment through diverse cell death induction for improved immunotherapy.
Ma J; Yuan H; Zhang J; Sun X; Yi L; Li W; Li Z; Fu C; Zheng L; Xu X; Wang X; Wang F; Yin D; Yuan J; Xu C; Li Z; Peng X; Wang J
J Control Release; 2024 Jun; 370():501-515. PubMed ID: 38703950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
